Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
d decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
d decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
Genes whose expression was decreased in RASMC subjected to Na<sup>+</sup>,K<sup>+</sup>-ATPase inhibition.
Published 2014“…Given <i>in italics</i> are genes whose differential expression was detected in ischemic tissue by whole genome microarray-based analysis <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0110597#pone.0110597-Mazzatti1" target="_blank">[12]</a>–<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0110597#pone.0110597-Leonard1" target="_blank">[18]</a>. …”
-
29
-
30
-
31
-
32
-
33
-
34
Beta-catenin signaling is decreased in intermediate progenitor cells.
Published 2010“…<p>(<b>A</b>) Cortex from E14.5 Axin2-d2EGFP transgenic mice stained for GFP (green), Tbr2 (red), and DNA (blue). …”
-
35
-
36
VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival.
Published 2018“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
-
37
-
38
-
39
-
40
Wnt5a expressing tumors demonstrate a decrease in markers of the basal tumor subtype.
Published 2014“…MMTV-Wnt1;MMTV-Wnt5a tumors demonstrated a significant decrease in K6-expressing cells as measured by T-test (* = p<0.05).…”